CA2364253A1 - Acide ouvert en dihydroxy et sels d'inhibiteurs de la hmg-co-a reductase - Google Patents

Acide ouvert en dihydroxy et sels d'inhibiteurs de la hmg-co-a reductase Download PDF

Info

Publication number
CA2364253A1
CA2364253A1 CA002364253A CA2364253A CA2364253A1 CA 2364253 A1 CA2364253 A1 CA 2364253A1 CA 002364253 A CA002364253 A CA 002364253A CA 2364253 A CA2364253 A CA 2364253A CA 2364253 A1 CA2364253 A1 CA 2364253A1
Authority
CA
Canada
Prior art keywords
compound
dihydroxy open
open acid
simvastatin
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002364253A
Other languages
English (en)
Inventor
Richard D. Tillyer
Paul J. Reider
Edward J. J. Grabowski
Feng Xu
Jose M. Vega
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2364253A1 publication Critical patent/CA2364253A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des procédés et des compositions pharmaceutiques pour l'inhibition de la HMG-CoA réductase, ainsi que pour le traitement et/ou la réduction du risque de maladies et d'états modifiés par l'inhibition de la HMG-CoA réductase. Lesdits procédés consistent à administrer par voie orale une dose efficace au plan thérapeutique d'un composé choisi parmi une statine d'acide ouvert en dihydroxy, un sel acceptable au plan pharmaceutique ou un ester, dans une forme galénique à effet retard, à un patient ayant besoin dudit traitement, la libération du composé par la forme galénique étant retardée jusqu'à ce que la forme galénique soit passée dans l'estomac.
CA002364253A 1999-03-08 2000-02-02 Acide ouvert en dihydroxy et sels d'inhibiteurs de la hmg-co-a reductase Abandoned CA2364253A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12322799P 1999-03-08 1999-03-08
US60/123,227 1999-03-08
US26474499A 1999-03-09 1999-03-09
US09/264,744 1999-03-09
PCT/US2000/002626 WO2000053173A1 (fr) 1999-03-08 2000-02-02 Acide ouvert en dihydroxy et sels d'inhibiteurs de la hmg-co-a reductase

Publications (1)

Publication Number Publication Date
CA2364253A1 true CA2364253A1 (fr) 2000-09-14

Family

ID=26821357

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002364253A Abandoned CA2364253A1 (fr) 1999-03-08 2000-02-02 Acide ouvert en dihydroxy et sels d'inhibiteurs de la hmg-co-a reductase

Country Status (9)

Country Link
EP (1) EP1161236A1 (fr)
JP (2) JP2002538202A (fr)
AR (1) AR022856A1 (fr)
AU (1) AU2866400A (fr)
CA (1) CA2364253A1 (fr)
CO (1) CO5150193A1 (fr)
PE (1) PE20001559A1 (fr)
SV (1) SV2002000036A (fr)
WO (1) WO2000053173A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523948A (ja) * 1999-11-04 2003-08-12 アンドルクス コーポレーション アミロイドβ前駆体障害の治療法
AU2001288724A1 (en) * 2000-09-06 2002-03-22 Merck & Co., Inc. Dihydroxy open-acid salt of simvastatin
WO2002030425A1 (fr) * 2000-10-12 2002-04-18 Nissan Chemical Industries, Ltd. Medicaments pour la prevention ou le traitement de complications du diabete
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
DK1355644T3 (da) 2001-01-26 2006-10-23 Schering Corp Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
HU230253B1 (hu) 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
AU2002324715B2 (en) * 2001-08-16 2009-03-12 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
KR20040026705A (ko) 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2005504091A (ja) 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
CN1612747A (zh) * 2002-01-09 2005-05-04 克鲁塞尔荷兰公司 促红细胞生成素在预防或治疗心力衰竭中的用途
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
WO2004043457A1 (fr) 2002-11-06 2004-05-27 Schering Corporation Inhibiteurs d'absorption de cholesterol pour le traitement de troubles auto-immuns
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
CA2517571C (fr) 2003-03-07 2011-07-05 Schering Corporation Azetidinones substituees , procedes pour leur preparation, formulations et utilisations de celles-ci
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
ATE428411T1 (de) * 2003-11-07 2009-05-15 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
ES2724549T3 (es) 2013-10-18 2019-09-12 Inst Nat Sante Rech Med ARN pequeños derivados de RNY como biomarcadores para trastornos relacionados con la aterosclerosis
WO2018213221A1 (fr) 2017-05-15 2018-11-22 University Of Cincinnati Compositions et méthodes de traitement de défauts dans un tissu cartilagineux avasculaire par administration directe d'un ou plusieurs métabolites de simvastatine
CN113134086B (zh) * 2020-01-20 2024-05-24 深圳市长卿医学研究院 一种降血脂的药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
CZ288545B6 (cs) * 1995-12-22 2001-07-11 Kowa Company, Ltd. Stabilizovaná farmaceutická kompozice na bázi kyseliny (E)-3,5-dihydroxy-7-[4´-4´´-fluorfenyl-2´-cyklopropylchinolin-3´-yl]-6-heptenové
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor

Also Published As

Publication number Publication date
SV2002000036A (es) 2002-02-05
JP2002538202A (ja) 2002-11-12
WO2000053173A1 (fr) 2000-09-14
EP1161236A1 (fr) 2001-12-12
CO5150193A1 (es) 2002-04-29
JP2000256191A (ja) 2000-09-19
AU2866400A (en) 2000-09-28
AR022856A1 (es) 2002-09-04
PE20001559A1 (es) 2001-01-16

Similar Documents

Publication Publication Date Title
US6569461B1 (en) Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
CA2364253A1 (fr) Acide ouvert en dihydroxy et sels d'inhibiteurs de la hmg-co-a reductase
AU764048B2 (en) Crystalline hydrated dihydroxy open-acid simvastatin calcium salt
EP1036563A1 (fr) Formulations retard a usage oral de simvastatine sous forme ouverte d'acide dihydroxy, de ses sels ou de ses esters
CN1867322B (zh) 结晶形式的γ-氨基丁酸类似物
AU2002310409B2 (en) Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
AU2010221167B2 (en) Oral dosage forms having a high loading of a gabapentin prodrug
HRP20030104A2 (en) Therapeutic combination
US20030176501A1 (en) Dihydroxy open-acid salt of simvastatin
EP3904335B1 (fr) Dérivé d'acide acétylsalicylique et traitement transdermale et transmucosale des indications associées à l'acide acétylsalicylique
US12208167B1 (en) Coated tablets for pH-dependent release of benzgalantamine
HK1029758A (en) Delayed-release oral formulation of dihydroxy open acid simvastatin and salts and esters thereof
EP2024316B9 (fr) Forme cristalline du leucotriene b4
HK1029786A (en) Crystalline hydrated dihydroxy open-acid simvastatin calcium salt
US9969674B2 (en) MMF-derivatives of ethyleneglycols
ES2281594T3 (es) Procedimiento para la preparacion de adsorbatos de atorvastatina en polvo de flujo libre.
US11795180B2 (en) Formulation of a pan-JAK inhibitor
WO2025147235A1 (fr) Composition d'association à dose fixe d'obicetrapib et d'ézétimibe
JP2008162949A (ja) チアゾリジンジオン化合物を含有する糖尿病治療薬

Legal Events

Date Code Title Description
FZDE Dead